
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9110193/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuromyelitis Optica and Non–Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.5	497
2	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
3	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.1	401
4	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.	9.0	357
5	Aquaporin-4 antibody–negative neuromyelitis optica. Neurology, 2013, 80, 2194-2200.	1.1	157
6	Acute Fulminant Demyelinating Disease. Archives of Neurology, 2007, 64, 1426.	4.5	148
7	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Multiple Sclerosis Journal, 2011, 17, 1067-1073.	3.0	144
8	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. JAMA Neurology, 2014, 71, 436.	9.0	133
9	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. Annals of Neurology, 2021, 89, 30-41.	5.3	123
10	Cognitive function in radiologically isolated syndrome. Multiple Sclerosis Journal, 2010, 16, 919-925.	3.0	116
11	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	7.2	115
12	NMO-IgG and Devic's neuromyelitis optica: a French experience. Multiple Sclerosis Journal, 2008, 14, 440-445.	3.0	107
13	Cognitive Functions in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 84-8.	4.5	98
14	Optical Coherence Tomography in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 920-3.	4.5	96
15	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1377-1384.	3.0	89
16	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis Journal, 2014, 20, 1086-1094.	3.0	87
17	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. Journal of Neurology, 2015, 262, 2329-2335.	3.6	86
18	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86

#	Article	IF	CITATIONS
19	Multiple sclerosis and depression: influence of interferon b therapy. Multiple Sclerosis Journal, 2003, 9, 284-288.	3.0	67
20	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology, 2020, 94, e1645-e1656.	1.1	66
21	A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1781-1793.	3.0	64
22	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	64
23	JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Multiple Sclerosis Journal, 2014, 20, 822-829.	3.0	62
24	New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunology Letters, 2005, 96, 11-26.	2.5	58
25	Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. Brain, 2015, 138, 284-292.	7.6	58
26	Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmunity Reviews, 2018, 17, 244-255.	5.8	58
27	Progress in understanding the pathophysiology of multiple sclerosis. Revue Neurologique, 2018, 174, 358-363.	1.5	56
28	A Benign Form of Neuromyelitis Optica. Archives of Neurology, 2011, 68, 918.	4.5	54
29	Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. Journal of Neurology, 2015, 262, 1936-1945.	3.6	53
30	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. PLoS ONE, 2015, 10, e0132033.	2.5	48
31	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Revue Neurologique, 2018, 174, 255-264.	1.5	47
32	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. Journal of Neurology, 2019, 266, 806-815.	3.6	47
33	Comparison of Simoa TM and Ella TM to assess serum neurofilamentâ€light chain in multiple sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 1141-1150.	3.7	45
34	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Multiple Sclerosis Journal, 2010, 16, 87-92.	3.0	43
35	Long-term Follow-up of Acute Partial Transverse Myelitis. Archives of Neurology, 2012, 69, 357.	4.5	42
36	Optical Coherence Tomography in Clinically Isolated Syndrome. Archives of Neurology, 2009, 66, 1373-7.	4.5	37

#	Article	IF	CITATIONS
37	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Multiple Sclerosis Journal, 2020, 26, 936-944.	3.0	37
38	Asymptomatic optic nerve lesions. Neurology, 2020, 94, e2468-e2478.	1.1	37
39	Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. European Radiology, 2014, 24, 3069-3075.	4.5	36
40	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurology, 2020, 77, 94.	9.0	36
41	Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. Journal of Neurology, 2012, 259, 2293-2298.	3.6	34
42	Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. Brain, 2019, 142, 903-915.	7.6	33
43	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. JAMA Network Open, 2021, 4, e2128271.	5.9	32
44	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. Journal of Neuroinflammation, 2022, 19, 62.	7.2	30
45	Managing MS in a changing treatment landscape. Journal of Neurology, 2011, 258, 728-739.	3.6	29
46	Proinflammatory B-cell profile in the early phases of MS predicts an active disease. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e431.	6.0	29
47	Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. Journal of Neurology, 2018, 265, 2251-2259.	3.6	29
48	Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. Neurology, 2020, 95, e733-e744.	1.1	29
49	Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. Brain Communications, 2021, 3, fcab185.	3.3	28
50	The longâ€ŧerm outcome of MOGAD: An observational national cohort study of 61 patients. European Journal of Neurology, 2021, 28, 1659-1664.	3.3	26
51	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 179, 53-64.	2.3	25
52	B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset. Neuroscience Letters, 2011, 487, 273-277.	2.1	25
53	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS ONE, 2017, 12, e0168834.	2.5	25
54	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. Journal of Neuroradiology, 2021, 48, 28-36.	1.1	24

#	Article	IF	CITATIONS
55	Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. Multiple Sclerosis Journal, 2016, 22, 649-658.	3.0	22
56	Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs. Journal of Neuroimmunology, 2007, 182, 80-88.	2.3	21
57	Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurology, 2013, 13, 211.	1.8	21
58	Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. Multiple Sclerosis Journal, 2014, 20, 1135-1139.	3.0	20
59	A metaâ€analysis comparing firstâ€line immunosuppressants in neuromyelitis optica. Annals of Clinical and Translational Neurology, 2021, 8, 2025-2037.	3.7	20
60	Longitudinal Retinal Changes in <scp>MOGAD</scp> . Annals of Neurology, 2022, 92, 476-485.	5.3	20
61	Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. Clinical Immunology, 2011, 139, 12-20.	3.2	19
62	Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 653577.	4.8	19
63	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.1	18
64	Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	16
65	Lumbar punctures: use and diagnostic efficiency in emergency medical departments. International Journal of Emergency Medicine, 2009, 2, 227-235.	1.6	15
66	Highâ€affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. British Journal of Pharmacology, 2015, 172, 1769-1782.	5.4	15
67	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. Journal of Neuroinflammation, 2020, 17, 128.	7.2	13
68	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). Multiple Sclerosis and Related Disorders, 2021, 53, 103076.	2.0	13
69	Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesion. Multiple Sclerosis Journal, 2019, 25, 1888-1895.	3.0	12
70	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. Multiple Sclerosis and Related Disorders, 2016, 6, 93-96.	2.0	10
71	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Multiple Sclerosis Journal, 2021, 27, 1556-1563.	3.0	9
72	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. Multiple Sclerosis Journal, 2021, 27, 729-741.	3.0	9

#	Article	IF	CITATIONS
73	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2009, 256, 134-136.	3.6	8
74	The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
75	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
76	A Spontaneous Model of Experimental Autoimmune Encephalomyelitis Provides Evidence of MOG-Specific B Cell Recruitment and Clonal Expansion. Frontiers in Immunology, 2022, 13, 755900.	4.8	8
77	Doubleâ€blind , randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderateâ€toâ€severe relapses of multiple sclerosis. Journal of Clinical Apheresis, 2020, 35, 281-289.	1.3	7
78	Neurological Involvement in Childhood Evans Syndrome. Journal of Clinical Immunology, 2019, 39, 171-181.	3.8	6
79	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal. Neurotherapeutics, 2022, 19, 476-490.	4.4	5
80	Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS. Multiple Sclerosis and Related Disorders, 2017, 11, 10-11.	2.0	4
81	Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. Multiple Sclerosis and Related Disorders, 2019, 33, 39-43.	2.0	4
82	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. Journal of Neuroradiology, 2021, 48, 170-175.	1.1	4
83	Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab. Cardiac Failure Review, 2021, 7, e09.	3.0	4
84	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. Multiple Sclerosis and Related Disorders, 2017, 18, 161-163.	2.0	3
85	Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure. Acta Neurologica Belgica, 2017, 117, 399-401.	1.1	3
86	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
87	Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms. Acta Neurologica Belgica, 2017, 117, 775-776.	1.1	1
88	Thérapeutiques et prise en charge de la sclérose en plaques. , 2017, , 145-216.		1
89	Diagnostics différentiels de la sclérose en plaques. , 2017, , 113-143.		0
90	Signes et symptômes de la sclérose en plaques. , 2017, , 3-78.		0

#	Article	IF	CITATIONS
91	Sclérose en plaquesÂ: les nouvelles approches physiopathologiques. Pratique Neurologique - FMC, 2019, 10, 112-117.	0.1	Ο
92	Diagnostic positif de la sclérose en plaques. , 2017, , 79-111.		0
93	Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. Neurology, 2021, 96, 295-296.	1.1	0